- Home
- CLLS vs INBX Comparison
CLLS vs INBX Comparison
Compare CLLS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- INBX
- Stock Information
- Founded
- CLLS 1999
- INBX 2010
- Country
- CLLS France
- INBX United States
- Employees
- CLLS N/A
- INBX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- INBX Health Care
- Exchange
- CLLS Nasdaq
- INBX Nasdaq
- Market Cap
- CLLS 143.4M
- INBX 178.5M
- IPO Year
- CLLS 2007
- INBX 2020
- Fundamental
- Price
- CLLS $1.59
- INBX $21.73
- Analyst Decision
- CLLS Buy
- INBX Hold
- Analyst Count
- CLLS 1
- INBX 1
- Target Price
- CLLS $4.00
- INBX N/A
- AVG Volume (30 Days)
- CLLS 48.2K
- INBX 120.3K
- Earning Date
- CLLS 08-05-2025
- INBX 08-12-2025
- Dividend Yield
- CLLS N/A
- INBX N/A
- EPS Growth
- CLLS N/A
- INBX N/A
- EPS
- CLLS N/A
- INBX 111.58
- Revenue
- CLLS $54,747,000.00
- INBX $200,000.00
- Revenue This Year
- CLLS $48.52
- INBX N/A
- Revenue Next Year
- CLLS $5.17
- INBX N/A
- P/E Ratio
- CLLS N/A
- INBX $0.20
- Revenue Growth
- CLLS 351.26
- INBX N/A
- 52 Week Low
- CLLS $1.10
- INBX $10.80
- 52 Week High
- CLLS $2.43
- INBX $22.28
- Technical
- Relative Strength Index (RSI)
- CLLS 56.98
- INBX 84.22
- Support Level
- CLLS $1.56
- INBX $13.97
- Resistance Level
- CLLS $1.49
- INBX $15.25
- Average True Range (ATR)
- CLLS 0.09
- INBX 1.10
- MACD
- CLLS 0.01
- INBX 0.66
- Stochastic Oscillator
- CLLS 80.00
- INBX 95.32
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.